PDMI with the FDA news today thius can fly big when they release!!
check news
SALT LAKE CITY, UT, Mar 05, 2010 (MARKETWIRE via COMTEX) -- Paradigm Medical
Industries, Inc. (PINKSHEETS: PDMI) announced today that it has been notified by
its Italian partner, Costruzione Strumenti Oftalmici (CSO), that all necessary
documents have been completed and submitted to the United States Food and Drug
Administration (FDA) for the Retimax(TM), also known as the Paramax. Paradigm is
the exclusive representative for this significant new product in the U.S.
market. "This new innovative device offers the earliest detection of glaucoma
currently available and will be an excellent addition to Paradigm's glaucoma
diagnostic products," said Stephen Davis, Paradigm's President and Chief
Executive Officer.
The Paramax (as it will be known in the United States) represents the third
product that Paradigm represents for CSO. Paradigm also represents CSO's
impressive corneal topographer, to be known in the U.S. as the Paravue 300, and
CSO's corneal topographer with Scheimpflug rotating camera, to be known in the
U.S. as the Surveyor 500. The Surveyor 500 with the Scheimpflug camera allows
for the complete analysis of the entire cornea and anterior segment of the eye.
Paradigm plans to begin active promotion of the Paravue 300 and the Surveyor 500
and will actively promote the Paramax immediately after it has received FDA
approval.
About Paradigm Medical Industries, Inc.
Headquartered in Salt Lake City, Utah, Paradigm Medical Industries, Inc. is a
medical device company that develops, manufactures and distributes ophthalmic
diagnostic instruments and related products for early detection of glaucoma and
other eye disorders. The Company's primary objective is to capture a niche
market within the glaucoma and ultrasound microscopy fields. Paradigm Medical
Industries markets its products to ophthalmologists, optometrists, universities,
and clinics throughout the United States and internationally.
This press release contains statements that, if not verifiable historic fact,
may be viewed as forward-looking statements that could predict future events and
outcomes with respect to Paradigm and its business. The predictions embodied in
these statements will involve risk and uncertainties and, accordingly, actual
results may differ significantly from the results discussed or implied in such
forward-looking statements.
For more information, please visit: www.paradigm-medical.com.
Contact:
Paradigm Medical Industries, Inc.
Stephen L. Davis
President and Chief Executive Officer
801-977-8970
www.paradigm-medical.com
News 
Market Data 
Discover 
